INDRAMEDCOHealthcare

Indraprastha Medical Corporation Limited

Hospital · ISIN INE681B01017 · BSE 532150 · NSE EQ · FV ₹10
Last price
₹336
+5.62%today
What this company does

Indraprastha Medical Corporation Limited operates in Hospital, part of the Healthcare sector. It booked ₹413 cr of revenue in its latest quarter (Q2 FY27) and kept 13.0% of sales as profit.

In the report:
80out of 100
Equitytale Health Score
Fortress

Healthier than 80% of companies in Healthcare, on all six measures of filed financials. Each measure is ranked against the 16–153 companies that reported it.

Measures financial condition, not whether to buy. Learn what this score means · How this is calculated

Price momentum
neutral
RSI (14)
45

At close. Not part of the score.

Profitability & returns84

How much profit it earns on the money it employs

Balance sheet87

How much it owes, and whether earnings cover the interest

Cash quality64

Whether reported profit actually arrives as cash

Growth & consistency71

Whether sales and profit have grown, and how steadily

Valuation73

What today's price implies, against our models or its peers

Governance & risk100

How much of the promoters' stake is pledged, and how much they hold · highest in its sector on what we could measure

Is this company doing well?
not investment advice
Strengths
✓ Makes a profit
✓ Sales up 8% vs last year
✓ Profit up 8% vs last year
✓ Promoters hold 51%
✓ No promoter shares pledged
✓ Strong 26% return on equity
✓ Virtually debt-free
✓ Turns profit into real cash
Watch-outs
None flagged from our data

What if I invest in INDRAMEDCO?

Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.

You would put in
₹12.00 lakh
120 instalments
At 15% a year, it would become
₹26.30 lakh

The slider starts at 15%, taken from this company's own free-cash-flow trend. That is history, not a forecast — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.

Key ratios · latest quarter + price
₹336▲ +5.62%
latest close · 2026-11-04
1-year return
+321.4%
52-wk low ₹5252-wk high ₹406
Is it cheap or expensive?
What you pay for the profits, book value and cash flow. Higher isn't automatically worse — it can signal faster growth.
P/E ratio14.4Low
LowAverageHigh
P/B ratio3.79High
Below bookModerateHigh
EV / EBITDA8.9Average
LowAverageHigh
How good is the business?
How much profit it earns from its money and its sales.
Return on equity26.3%Strong
WeakFairStrong ▸15%
Return on capital32.9%Strong
WeakFairStrong
Net margin13.0%Decent
ThinDecentStrong
EBITDA margin20.8%Healthy
ThinDecentHealthy
Is it financially safe?
How much it owes, and whether it can comfortably cover it.
Debt to equity0.00Comfortable
LowModerateHigh ▸1
Interest cover44.4×Strong
RiskyOkayStrong ▸5×
Current ratio2.30Ample
Tight ◂1HealthyAmple
More figures
Market cap
₹3,083 cr
Book value
₹89
EPS
₹5.84
latest quarter
Net debt
₹-6 cr
more cash than debt
Enterprise value
₹3,076 cr
EBITDA
₹344 cr
annualised
EBIT
₹295 cr
annualised
Operating margin
17.9%
Return on assets
19.2%
Earnings yield
6.95%
P/S
1.87
Sales / share
₹180.1
Tax rate
25.7%
Face value
₹10
Shares
9.2 cr
Working capital
₹290 cr
Current assets
₹513 cr
Current liabilities
₹223 cr
Delivery %
55.8%
Strong / safeFairWeak / riskyValuation — a level, not good/badBands are general rules of thumb, not advice.

P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-11-04.

Worth vs price · from the FY 2025 report & filings
not investment advice
Looks overpricedHigh confidence
Median of 3 models ₹224 vs market price ₹336 — price is 50% above it
Safety cushion-50.3%(target ≥ +20%)
Models span ₹195–₹231, midpoint ₹224
Model ₹224
Price ₹336
Cheap sideExpensive side

An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.

P&L · Q2 FY27 (consolidated)
Revenue from Operations₹413 cr
Other Income₹9 cr
Total Income₹421 cr
Cost of Materials₹67 cr
Purchases of Stock-in-Trade₹0 cr
Employee Benefit Expense₹79 cr
Finance Costs₹2 cr
Depreciation & Amortisation₹12 cr
Other Expenses₹189 cr
Total Expenses₹349 cr
Profit before Tax₹72 cr
Tax Expense₹18 cr
Net Profit₹54 cr
Net margin on total income12.7%
Where the money goes · Q2 FY27
% of total income
Materials + stock-in-trade₹67 cr16.0%
Employee benefit expense₹79 cr18.6%
Finance costs₹2 cr0.4%
Depreciation & amortisation₹12 cr2.9%
Other expenses₹189 cr45.0%
Tax expense₹18 cr4.4%
Profit for the period₹54 cr12.7%
Total income ₹421 cradds up to ₹100 ✓
Quarterly results · consolidated (₹ cr)
MetricQ4 FY26Q1 FY27Q2 FY27
Revenue365 cr406 cr413 cr
Total income372 cr415 cr421 cr
Expenses317 cr340 cr349 cr
Profit before tax55 cr75 cr72 cr
Tax13 cr19 cr18 cr
Net profit (owners' share)42 cr56 cr54 cr
Net margin (owners' share, on revenue)11.4%13.8%13.0%
EPS (₹)4.556.095.84
YoY (latest quarter): total income +8.5% · net profit +8.3%
Balance sheet & cash flow · as of Sep 2026
Debt-free
Total assets
₹1,118 cr
Shareholder equity
₹814 cr
parent shareholders
Total debt
₹0 cr
Cash
₹6 cr
Cash flow · H1 FY27
Operating
₹109 cr
Investing
₹-101 cr
Financing
₹-6 cr
Peer comparison
Hospital · by market value
CompanyPriceMarket capP/E
Apollo Hospitals Enterprise Limited₹8,440₹1.21 L cr52.2
Max Healthcare Institute Limited₹896₹87,160 cr52.6
Manipal Health Enterprises Limited₹642₹75,740 cr81.9
Fortis Healthcare Limited₹786₹59,306 cr55.6
Narayana Hrudayalaya Ltd.₹1,871₹38,228 cr31.6
Global Health Limited₹1,326₹35,621 cr40.4
Aster DM Quality Care Limited₹681₹35,303 cr549.5
Krishna Institute of Medical Sciences Limited₹731₹30,681 cr175.6
Dr. Agarwal's Health Care Limited₹513₹16,256 cr89.7
Same industry · latest reported numbers · not a recommendation.
Corporate actions
Dividend yield
1.19%
trailing 12 months
Dividend / share (TTM)
₹4
Last dividend
₹4
ex 18 Sep 2026
ActionDetailEx-date
Dividend₹4 / share18 Sep 2026
Dividend₹4.5 / share18 Sep 2025
Dividend₹4.5 / share13 Sep 2024
Dividend₹3 / share15 Sep 2023
Dividend₹2.5 / share15 Sep 2022
Dividend₹1.6 / share12 Sep 2019
Who owns it · 2026-09-30
No pledge
Promoter
51.0%
FII / Foreign
2.4%
DII / Domestic
1.8%
Retail / others
44.8%
Smart-money activity
Bulk / block deals
short— · NSE553 Sep 26
short— · NSE7027 May 26
short— · NSE5110 Apr 26
Stake changes
SoldHDFC Bank Limited→ 2.45% · 27.82 L4 Apr 24
SoldHDFC Bank Ltd→ 5.49% · 20.24 L28 Feb 24
BoughtHDFC Bank Limited→ 6.71% · 61.47 L1 Jul 23
What shareholders were asked to approve
4 proposals passed only on promoter votes

A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.

Yearly shareholder meeting · 24 Sep 2026
See the official result
1
Adoption of financial statements - To receive, consider and adopt the audited financial statements of the Company for the year ended 31st March, 2026, together with the Reports of the Board of Directors and Auditors thereon.
Backed by 100% of shareholders other than promotersneeded 50%
20.88 L votes for, 271 against · 0% of mutual funds and other big investors said no
2
Declaration of Dividend – To declare dividend on Equity Shares at the rate of Rs. 4.00 per equity share (40%) of face value of Rs. 10/- each for the financial year ended 31st March, 2026.
Backed by 100% of shareholders other than promotersneeded 50%
20.88 L votes for, 467 against · 0% of mutual funds and other big investors said no
3
Re-Appointment of Retiring Director in place of Prof. (Dr.) Mahesh Verma (DIN 08997324), who retires by rotation and being eligible, offers himself for re-appointment
Backed by 96% of shareholders other than promotersneeded 50%
20.07 L votes for, 81,598 against · 4% of mutual funds and other big investors said no
4
Re-Appointment of Retiring Director in place of Dr Suneeta Reddy (DIN 000001873), who retires by rotation and being eligible, offers herself for re-appointment
Promoters had a personal stake in this
Backed by 94% of shareholders other than promotersneeded 50%
19.67 L votes for, 1.21 L against · 6% of mutual funds and other big investors said no

Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.

Who controls this company, and what it pays them

Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.

The promoter group — 14 named members
owning 51.0% between them · as of 2026-09-30
PRESIDENT OF INDIA26.00%
APOLLO HOSPITALS ENTERPRISE LIMITED22.02%
WEDGEWOOD HOLDINGS LIMITED1.61%
PCR INVESTMENTS LIMITED0.42%
PRATAP C REDDY0.26%
PREETHA REDDY0.22%
SUCHARITHA P REDDY0.18%
SUNEETA REDDY0.15%

Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.

How the stock has moved · adjusted for splits & bonuses
Data from primary exchange filings · analysis tool, not investment advice.